Skip to main content
. 2015 Sep 29;6(36):39062–39072. doi: 10.18632/oncotarget.5393

Figure 4. IGKV somatic hypermutation in myeloblasts and mature myeloid cells.

Figure 4

A. Alignment of three frequently used IGKV sequences (IGKV3-20*01, IGKV3-15*01 and IGKV1-9*01) from AML patients and patients with non-hematopoietic neoplasms (non-AML). The result showed that mutations frequently occurred in AML-derived IGKV but not in non-hematopoietic neoplasms-derived IGKV. B. The frequency of mutations in framework regions (FWR) and complementary determination regions (CDR). The mutation rate of all mutations and replacement mutation (R mutation) were presented.